Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dyax Corp receives orphan drug designation from the U.S. FDA for DX-2930 in hereditary angioedema


Thursday, 5 Dec 2013 08:00am EST 

Dyax Corp:Says that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE). 

Company Quote

9.04
-0.05 -0.55%
24 Jul 2014